Cory Renauer
Value, research analyst, biotech, small-cap

Cubist Pharmaceuticals: Doomsday Preparation Update

Cubist Pharmaceuticals (CBST) is a highly profitable, commercial stage biopharmaceutical company based in Lexington, Massachusetts. It began producing positive cash flows in 2007 and hasn't looked back, largely on the strength of daptomycin (Cubicin), an antibiotic it purchased from Eli Lilly (NYSE:LLY) in 1997. In 2012, daptomycin comprised 93% of Cubist's total revenue. With only a few years of daptomycin exclusivity remaining, the company is facing armageddon. Here's a look at how much Cubist stands to lose, when they might lose it, and what they're doing to prepare for the impending loss of Cubicin exclusivity.

Entereg, the first responder

The company's efforts to diversify revenue sources are tipping the scales in the right direction, largely on the back...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details